NovaBay Receives First Large NeutroPhase Order From China Pioneer Pharma

By September 25, 2014

NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that its partner China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a leading marketer of branded pharmaceutical products and medical devices in China, has placed its first order for NovaBay’s NeutroPhase® Skin and Wound Cleanser. NovaBay will be shipping NeutroPhase to China later this year to support Pioneer’s launch of the product in early 2015 throughout mainland China.

The order follows the clearance in early September of NeutroPhase for sale in China by China’s Food and Drug Administration.

“We believe that China will be significant market for NeutroPhase because the product has the potential to bring a major improvement in medical care in China,” said Dr. Ron Najafi, Chairman and CEO of NovaBay.

NeutroPhase offers new options for managing both the chronic wounds of diabetes patients and for deadly flesh-eating disease (necrotizing fasciitis). China is now experiencing what experts call a ‘catastrophic’ epidemic of diabetes. According to estimates provided by the International Diabetes Federation and the American Medical Association, approximately 100 million Chinese already suffer from this condition and from the side effects of diabetes, such as diabetic ulcers and other chronic wounds.  NeutroPhase is ideally formulated for the management of these types of wounds and many others such as venous stasis ulcers and pressure ulcers that can seriously affect a patient’s morbidity and mortality.

NovaBay’s FDA-cleared NeutroPhase has shown remarkable properties in the management of these categories of wounds. As John Crew, M.D., FACS states in the peer-reviewed International Journal of Burns and Trauma, “Patients showed a profound improvement and marked accelerated rates of wound healing using NeutroPhase with and without NPWT (negative pressure wound therapy). NeutroPhase was non-toxic to living tissues.”

NeutroPhase contains a substance produced naturally by the immune system as a first defense against microbial invaders. Laboratory tests show that NeutroPhase not only kills bacteria that infect wounds and cause necrotizing fasciitis, it also neutralizes toxins produced by both bacteria and the immune system that impede healing and destroy healthy tissue. Those properties enable NeutroPhase to address acute infections and to help promote the healing of chronic wounds.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: (1) its advance clinical stage Aganocide® compounds; and (2) its three commercial products containing Neutrox™: NeutroPhase® for wound care, Advanced i-Lid™ Cleanser for the eye care market, and CelleRx™  for the dermatology market.

About China Pioneer Pharma Holdings, Limited.
China Pioneer Pharma is one of the largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China. Founded in 1996, Pioneer has an impressive 18-year operating history. Currently, China Pioneer Pharma has a product portfolio of over 30 pharmaceutical products covering a wide range of therapeutic areas, and medical devices covering four medical specialties. And it has over 240 in-house marketing and promotion employees, over 1,000 third-party promotion partners and over 500 distributors. China Pioneer Pharma sells its products through its nationwide marketing, promotion and channel management service network to a total of over 26,000 hospitals and other medical institutions and over 95,000 pharmacies across 31 provinces, municipalities and autonomous regions in China. For more information, please visit www.pioneer-pharma.com.

Forward-looking Statements.
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding regulatory approvals for our products, the anticipated market acceptance of our products, and the company’s expected future financial results. The words “believe” “potential” and “anticipate” are intended to identify these forward-looking statements.  Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in product development, clinical trials, regulatory approval, production and marketing of the company’s products, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to the company and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

For NovaBay NeutroPhase purchasing information, please contact:
Toll-Free: 1-800-890-0329
Contact a NeutroPhase Distributor

For investor information, please contact:
Thomas J. Paulson  
Chief Financial Officer
510-899-8809
Contact Thomas Paulson

TOP